Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYCR1 | P32322 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 5/20 | 0.41 |
| ▸ | PNMT | P11086 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31033443 | 0.98 | PYCR1 (0.45) | PYCR1CYP2A6CCR5IDO1PNMT | |
| SCHEMBL980222 | 0.83 | TAAR1 (0.52) | PYCR1IDO1CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL1196832 | 0.82 | CYP2A6 (0.44) | PYCR1CYP2A6CCR5IDO1PNMT | |
| Hydrochloric Acid SCHEMBL23093580 | 0.80 | CYP2A6 (0.43) | PYCR1CYP2A6CCR5IDO1PNMT | |
| SCHEMBL26078400 | 0.79 | PYCR1 (0.47) | PYCR1IDO1CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL979069 | 0.79 | PYCR1 (0.47) | PYCR1IDO1CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL29485890 | 0.79 | PYCR1 (0.47) | PYCR1IDO1CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL17664007 | 0.78 | MEN1 (0.52) | PYCR1CCR5IDO1CYP3A4ALOX15 | |
| SCHEMBL701343 | 0.78 | CYP2A6 (0.48) | CYP2A6IDO1PNMTCYP3A4CYP1A2 | |
| SCHEMBL257088 | 0.77 | PYCR1 (0.50) | PYCR1IDO1CYP3A4CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4705281-A1 | COMPOUNDS FOR TREATING CANCER | Genesis Molecular AI, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| WO-2025215110-A1 | NEW AMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS SOS1 INHIBITORS | LES LABORATOIRES SERVIER (FR) | 2025-10-16 | — | — | WO | disclosed |
| US-20250092027-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2025-03-20 | — | — | US | disclosed |
| CN-119264764-A | Zinc-containing coating film | 东丽先端材料研究开发（中国）有限公司 | 2025-01-07 | — | — | CN | disclosed |
| WO-2024229121-A1 | COMPOUNDS FOR TREATING CANCER | GENESIS THERAPEUTICS, INC. (US) | 2024-11-07 | — | — | WO | disclosed |
| US-12071429-B2 | Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity | ASTEX THERAPEUTICS LIMITED (GB) | 2024-08-27 | — | — | US | disclosed |
| US-20240083857-A1 | 2-Methyl-Quinazolines | Bayer Pharma AG (DE) | 2024-03-14 | — | — | US | disclosed |
| US-20230265109-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2023-08-24 | — | — | US | disclosed |
| EP-4151633-A1 | INTERMEDIATES OF ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | Astex Therapeutics Limited (GB) | 2023-03-22 | — | — | EP | disclosed |
| EP-3356350-B1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | ASTEX THERAPEUTICS LTD (GB) | 2022-11-16 | — | — | EP | disclosed |
| US-20070293478-A1 | Substituted quinolones | BAYER HEALTHCARE AG (DE) | 2007-12-20 | — | — | US | disclosed |
| EP-1768973-B1 | SUBSTITUTED QUINOLONES | AICURIS GMBH & CO KG (DE) | 2007-12-05 | — | — | EP | disclosed |
| EP-1768973-B1 | SUBSTITUTED QUINOLONES | AICURIS GMBH & CO KG (DE) | 2007-12-05 | — | — | EP | disclosed |
| CN-101031557-A | Substituted quinolones | AICURIS GMBH & CO KG (DE) | 2007-09-05 | — | — | CN | disclosed |
| WO-2007090579-A2 | SUBSTITUTED QUINOLONES III | AICURIS GMBH & CO. KG (DE) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007090579-A2 | SUBSTITUTED QUINOLONES III | AICURIS GMBH & CO. KG (DE) | 2007-08-16 | — | — | WO | disclosed |
| EP-1768973-A1 | SUBSTITUTED QUINOLONES | AiCuris GmbH & Co. KG (DE) | 2007-04-04 | — | — | EP | disclosed |
| WO-2007003308-A1 | SUBSTITUTED QUINOLONES II | AICURIS GMBH & CO. KG (DE) | 2007-01-11 | — | — | WO | disclosed |
| WO-2007003308-A1 | SUBSTITUTED QUINOLONES II | AICURIS GMBH & CO. KG (DE) | 2007-01-11 | — | — | WO | disclosed |
| WO-2006008046-A1 | SUBSTITUTED QUINOLONES | AICURIS GMBH & CO. KG (DE) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12071429-B2 | Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity | TP53, MDM2, TP53BP1 | PYCR1 3011/4885CYP2A6 2658/4885CCR5 4317/4885 |
| US-20240083857-A1 | 2-Methyl-Quinazolines | NRAS, KRAS, KSR2 | PYCR1 2864/4885CYP2A6 993/4885CCR5 977/4885 |
| US-20250092027-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | TP53, MDM2, TP53BP1 | PYCR1 2922/4885CYP2A6 2566/4885CCR5 4347/4885 |
| US-20070293478-A1 | Substituted quinolones | IRF3, TPMT, NQO2 | PYCR1 2912/4885CYP2A6 381/4885CCR5 418/4885 |
| US-20230265109-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | PYCR1 1729/4885CYP2A6 1609/4885CCR5 2375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.